WHWK: Held by 6 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics, Inc.

WHWK

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Short interest: 2.2% of float.

BiotechnologyCEO: David J. LennonIPO: 2017Website ↗

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.3/10

6 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 6 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

6 fund convergence

Avoro Capital AdvisorsHeld 7Q

Baker Bros. Advisors

BVF Partners

EcoR1 Capital

RA Capital Management

OrbiMed AdvisorsHeld 4Q

Position history (shares)

Avoro Capital Advisors

EcoR1 Capital

OrbiMed Advisors

AI Signal

Signal Note: WHWK

BVF's exit contrasts sharply with concentrated conviction from six specialist biotech funds (EcoR1, Avoro, Baker Bros., OrbiMed, RA Capital), suggesting potential disagreement on near-term clinical/capital trajectory or valuation. The six-fund convergence indicates high conviction on the underlying science, though BVF's departure warrants scrutiny on cash runway, upcoming catalysts, and dilution risk—factors that would justify a value investor's exit despite peer conviction.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Aug 14, 2025

$15.2M

3 funds

Nov 14, 2025

$13.3M

2 funds

Feb 17, 2026

$10.1M

1 fund

Mar 16, 2026

$6.9M

1 fund

-80% total institutional value over 15 quarters

Short Interest

Short Shares

780K

Change

+8.0%

Days to Cover

4.0

% of Float

2.2%

Settlement

Apr 15, 2026

Short interest over 5 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GOrbiMed Advisors8.9%May 15, 2025

SC 13D/AAvoro Capital Advisors18.0%Mar 4, 2025

SC 13G/AEcoR1 Capital1.4%Feb 14, 2025

SC 13D/AAvoro Capital Advisors11.6%Dec 23, 2024

SC 13GEcoR1 Capital7.5%Sep 3, 2024

SC 13D/AAvoro Capital Advisors11.7%Sep 26, 2022

SC 13D/AAvoro Capital Advisors8.8%Aug 30, 2021

Position Details

Avoro Capital AdvisorsMar 16, 2026

Start free trialfor share counts, dollar values & AI analysis

57 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

ACRV1 fund ALGS1 fund NUVL1 fund PHVS1 fund PRLD1 fund TSHA1 fund XENE1 fund IRON1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer